| Ytd | -10.12% | |
| 1y | 16.56% |
| Open | 3.68 | Prev Close | 3.69 | Low | 3.64 | High | 3.73 | Mkt Cap | 220.96M |
| Vol | 6.65K | Avg Vol | 335.41K | EPS | -0.97 | P/E | -3.80 | Forward P/E | -2.66 |
| Beta | 0.49 | Short Ratio | 12.51 | Inst. Own | 54.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 3.98 | 200-d Avg | 4.12 | 1yr Est | 15.60 |
OBIO News
B. Riley Securities analyst Kyle Bauser maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy
HC Wainwright & Co. analyst Yi Chen reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Bu
Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.33) per share which beat the a
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"),
$15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, b
Payment fulfills previously disclosed funding commitment of $20 million and supports planned complet
Together, the two BDDs for AVIM Therapy cover indications that encompass both the broader population
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly earnings of $0.26 per share which beat the a
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")),
Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and
TD Cowen analyst Joshua Jennings initiates coverage on Orchestra BioMed Hldgs (NASDAQ:OBIO) with
Chardan Capital analyst Keay Nakae maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and
Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.40) per share which beat the a
U.S. stocks traded slightly lower, with the Dow Jones dropping around 30 points on Thursday. Here ar